Browse EX-10 agreements

**LATIGO BIOTHERAPEUTICS, INC. **

**SEVERANCE PLAN **

**AND **

**SUMMARY PLAN DESCRIPTION **

**APPROVED BY THE BOARD OF DIRECTORS: July 13, 2026 **

1. Introduction. The purpose of this Latigo Biotherapeutics, Inc. Severance Plan (the “Plan”) is to provide specified severance benefits to eligible employees of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA (as defined below). This Plan shall supersede any existing severance plan or individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee’s separation from the Company. This document constitutes both the written instrument under which the Plan is maintained and the

…

**LATIGO BIOTHERAPEUTICS, INC. **

**EXECUTIVE EMPLOYMENT AGREEMENT **

**for **

**NEIL SINGLA, M.D. **

This Executive Employment Agreement (this “Agreement”), is made and entered into July 15, 2026, by and between Neil Singla, M.D. (“Executive”) and Latigo Biotherapeutics, Inc. (the “Company”). This Agreement is contingent and shall only be effective immediately prior to such time as the U.S. Securities and Exchange Commission declares the Company’s registration statement on Form S-1 effective (such date, the “Effective Date”).

WHEREAS, the Company and Executive desire to enter into an agreement of employment on the terms set forth herein to amend and restate the terms of the Executive’s continued employment with the Company.

WHEREAS, as of the Effective Date, this Agreement shall supersede and replace the Offer Letter between the Executive and the Company, dated March 16, 2024 (the “Prior Agreement”).

…

**Exhibit 10.8 **

**LATIGO BIOTHERAPEUTICS, INC. **

January 30, 2026

Tim Lugo

Re:	**Separation Agreement **

Dear Tim:

This letter sets forth the substance of the separation agreement (the “Agreement”) that Latigo Biotherapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.

1. SEPARATION. Your employment termination date will be January 30, 2026 (the “Separation Date”). You understand and agree that you are not authorized to hold yourself out as being employed or affiliated with the Company in any way following the Separation Date.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

**APPROVED BY THE STOCKHOLDERS: [    ] **

1.	**GENERAL; PURPOSE. **

(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2026 EQUITY INCENTIVE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

**APPROVED BY THE STOCKHOLDERS: [     ] **

1.	**GENERAL. **

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding Awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

**CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. **

LEASE

by and between

BMR-10255 SCIENCE CENTER LP,

a Delaware limited partnership

and

BLOSSOMHILL THERAPEUTICS, INC.,

a Delaware corporation

BioMed Realty form dated 11/18/20

---

**Table of Contents **

…

**CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. **

**BLOSSOMHILL THERAPEUTICS, INC. **

**CONSULTING AGREEMENT **

**Effective Date: August 15, 2025 **

**This Consulting Agreement **(the “Agreement”) is made as of the Effective Date set forth above by and between BlossomHill Therapeutics, Inc., a Delaware corporation (“Client”) and the consultant named on the signature page hereto (“Consultant”).

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**SEVERANCE PLAN **

**AND **

**SUMMARY PLAN DESCRIPTION **

**APPROVED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

1. Introduction. The purpose of this BlossomHill Therapeutics, Inc. Severance Plan (the “Plan”) is to provide specified severance benefits to eligible employees of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumstances. This Plan is an “employee welfare benefit plan,” as defined in Section 3(1) of ERISA (as defined below). This Plan shall supersede any existing severance plan or individual agreement between the Company and any Covered Employee (as defined below) and any other plan, policy or practice, whether written or unwritten, maintained by the Company with respect to a Covered Employee, in each case to the extent that such agreement, plan, policy or practice provides for equity acceleration or severance benefits upon the Covered Employee’s separation from the Company. This document constitutes both the written instrument under which the Plan is maintained an

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**STOCK OPTION GRANT NOTICE **

**(2026 EQUITY INCENTIVE PLAN) **

BlossomHill Therapeutics, Inc. (the “Company”), pursuant to its 2026 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.

…

**AMENDMENT NO. 3 **

**TO THE **

**2020 EQUITY INCENTIVE PLAN **

This AMENDMENT No. 3 TO 2020 EQUITY INCENTIVE PLAN is made as of March 21, 2025, by BLOSSOMHILL THERAPEUTICS, INC., a Delaware corporation (the “Company”).

**RECITALS **

WHEREAS, 6,537,582 shares of Common Stock of the Company have been reserved for issuance under the 2020 Equity Incentive Plan, as amended by Amendment No. 1, dated as of February 26, 2021, and Amendment No. 2, dated as of July 12, 2023 (the “Plan”);

WHEREAS, to further the growth and success of the Company by providing compensation commensurate with maintaining a competitive position in the market to attract and retain key personnel, the Board and the requisite number of stockholders, having acted by written consent, approved an increase in the aggregate number of shares available for issuance under the Plan to 9,003,346 total shares of Common Stock; and

WHEREAS, all capitalized terms not defined herein shall have the same meanings as set forth in the Plan.

**AGREEMENT **

…

***INDEMNIFICATION AGREEMENT ***

This Indemnification Agreement is dated as of _________, 2026 (this “Agreement”) and is between BlossomHill Therapeutics, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).

Background

The Company believes that in order to attract and retain highly competent persons to serve as directors or in other capacities, including as officers, it must provide such persons with adequate protection through indemnification against the risks of claims and actions against them arising out of their services to and activities on behalf of the Company.

The Company desires and has requested Indemnitee to serve as a director and/or officer of the Company and, in order to induce the Indemnitee to serve in such capacity, the Company is willing to grant the Indemnitee the indemnification provided for herein. Indemnitee is willing to so serve on the basis that such indemnification be provided.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2020 EQUITY INCENTIVE PLAN **

**STOCK OPTION GRANT NOTICE **

BlossomHill Therapeutics, Inc. (the “Company”) hereby grants to you an Option (the “Option”) to purchase shares of the Company’s Common Stock under the Company’s 2020 Equity Incentive Plan (the “Plan”). The Option is subject to all the terms and conditions set forth in this Stock Option Grant Notice (this “Grant Notice”), in the Stock Option Agreement and in the Plan, which are attached to and incorporated into this Grant Notice in their entirety.

…